Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2053 SAD in Subjects With Normal or Elevated LDL-C
NCT06229548Phase 1Completed
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypercholesterolemia comparing SYH2053 SAD with Placebo SAD (2 arms). Primary endpoint: Number of Participants with Treatment Related Adverse Events up to 57 days. Started Jan 2024; status: completed.
02
Drugs
SYH2053
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06229548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06229548.